NCT05533008View on ClinicalTrials.gov

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

June 11, 2020

Study Completion Date

June 11, 2020

Conditions
Hemodialysis
Interventions
DRUG

CR845 0.5 mcg/kg

IV CR845 0.5 mcg/kg as a bolus injection

OTHER

Placebo

IV Placebo as a bolus injection

Trial Locations (5)

48066

Cara Therapeutics Study Site, Roseville

55404

Cara Therapeutics Study Site, Minneapolis

64111

Cara Therapeutics Study Site, Kansas City

06606

Cara Therapeutics Study Site, Bridgeport

06112

Cara Therapeutics Study Site, Hartford

Sponsors
All Listed Sponsors
lead

Cara Therapeutics, Inc.

INDUSTRY